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Motility disturbances of the colon can give significant symptoms in patients with diabetes
mellitus. Constipation is a common complaint in these patients. Diarrhea associated with a
generalized autonomic neuropathy can be very troublesome.
There is a disturbance in the gastrocolonic response to eating in patients with diabetes
mellitus who have constipation. These patients have no postprandial increase in colonic mo-
tility. However, their colonic smooth muscle contracts normally to the exogenous administra-
tion of neostigmine or metoclopramide.
Stool softeners used in combination with the smooth muscle stimulants (neostigmine or
metoclopramide) are helpful in treating constipation in patients with diabetes mellitus. Diar-
rhea can be treated with loperamide or diphenoxylate. Biofeedback may be useful in treating
incontinence associated with diarrhea in these patients.
Gastrointestinal motility disturbances are common among diabetic patients
[1,2,3]. Many patients are free ofsignificant gastrointestinal symptoms, while others
develop disabling syndromes. Esophageal motor dysfunction [4,5], gastroparesis [6],
and diarrhea [7,8] have been the most frequently reported and studied intestinal
manifestations of diabetes mellitus. Despite the presence of significant symptoms
related to colonic dysfuncton, the literature on the colonic complications ofdiabetes
mellitus is sparse. In this article we review the clinical manifestations, pathogenesis,
and approach to treatment of diabetic colonic dysfunction.
Thepotential colonic complications ofdiabetes mellitus are listed in Table 1. Con-
stipation has been cited as the most common gastrointestinal complaint of diabetic
patients [1,2,3]. The true incidence is difficult to ascertain compared to the normal
population, but severe symptoms have been reported in 20 percent of patients with
diabetic neuropathy [9]. Profound constipation with massive fecal impaction may
occur [1,10]. These patients may develop marked abdominal distention and severe
nausea and vomiting associated with electrolyte disturbances. Prolonged fecal im-
paction may lead to stercoral ulcerations and perforation.
Unexplained chronic diarrhea, with or without steatorrhea, can be a major prob-
lem in some diabetic patients. Steatorrhea has generally been attributed to pan-
creatic insufficiency, celiac disease, or bacterial overgrowth of the small intestine
[1,2,3]. In these patients the colon appears to play a secondary or permissive role in
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Potential Colonic Complications of Diabetes
Constipation
Fecal impaction
Stercoral ulceration or perforation
Megacolon or megasigmoid
Barium impaction
Volvulus
Diarrhea
Fecal incontinence
the production of diarrhea. In the absence of steatorrhea, colonic dysfunction may
be a primary contributor to diabetic diarrhea.
Gross atonic dilation of the colon simulating organic obstruction has been
reported in a diabetic patient with prolonged intractable diarrhea [11]. At autopsy,
ulcerations were present in the descending and sigmoid colon. The precise nature of
the colonic lesion in this patient could not be identified, but either stercoral ulcera-
tion or segmental colitis seemed most likely. This case suggests that diabetic
enteropathy should be included in the differential diagnosis of megacolon.
Berenyi and Schwarz described 13 patients with autonomic dysfunction and
marked sigmoid dilation [12]. Diabetes mellitus was present in nine patients, while
the others suffered from Parkinson's disease or traumatic paraplegia. Diarrhea oc-
curred in the majority of patients, and sigmoid volvulus was a frequent complica-
tion. The authors suggested an association between diabetic visceral neuropathy and
the megasigmoid syndrome.
Read and associates studied a varied group ofpatients with fecal incontinence and
diarrhea [13]. Diabetes mellitus was felt to be the major contributing factor in 28
percent oftheir patients. Stool volume, sphincter pressure, and ability to retain rec-
tally infused saline were evaluated. Most diabetic patients had low stool volumes,
low sphincter pressures, and an impaired ability to retain saline infused into the rec-
tum. These results suggested weakness ofthe anal sphincter as the major mechanism
responsible for the incontinence. Similarly, Schiller and associates compared
diabetics with fecal incontinence to continent diabetics and non-diabetic controls
[14]. They found that the onset of incontinence usually coincided with the onset of
chronic diarrhea. Moreover, their results confirmed that the mechanism of incon-
tinence in diabetic patients is related to internal anal sphincter dysfunction. Wald
demonstrated an absent or weakened external sphincter contraction and a high nor-
mal threshold of rectal sensation (30 ml) in diabetic patients with fecal incontinence
[15].
Diabetes mellitus is one of the four endocrine disorders considered to be second-
ary causes of the chronic intestinal pseudo-obstruction syndrome [16]. The other
disorders are myxedema, hypoparathyroidism, and pheochromocytoma.
Significant colonic dysfunction generally occurs in the setting of diabetic
neuropathy, as is true of motor abnormalities elsewhere in the gastrointestinal tract.
Widespread involvement of the autonomic nervous system may occur, and many of
these patients will demonstrate orthostatic hypotension, impotence, neurogenic
bladder, anhidrosis, or vasomotor instability [17]. Vascular responses to the
Valsalva maneuver and sustained handgrip have been proposed as a practical objec-
tive assessment of the integrity of the autonomic nervous system in diabetic patients
[18].
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No specific predisposing factors have been identified for colonic dysfunction in
diabetes mellitus. Analysis of the clinical profile of the patients in our study of
diabetic constipation failed to reveal a correlation between duration of disease or
total daily insulin dose and severity of symptoms. However, patients with an early
age of onset of clinical diabetes, regardless of duration, tended to have the worst
symptoms [17].
There are no pathognomonic radiographic findings on barium enema for diabetes
mellitus. A dilated ahaustral colon, similar to that associated with laxative abuse,
may occur in some patients. Significant symptoms may be present, however, in the
absence of radiographic abnormalities. In other disorders associated with a
hypomotile colonic state, such as scleroderma, severe barium impaction has oc-
curred [20]. This should be kept in mind when barium studies are performed on
diabetic patients with severe colonic hypomotility. Thorough cleansing maneuvers
should be performed post-examination.
PATHOGENESIS
General
The movement of material through the colon is controlled by the contractile pat-
tern of the colonic smooth muscle [21]. Studies in the cat showed that colonic
segmental contractile activity propagates toward the cecum, allowing complete ab-
sorption ofelectrolytes and water in the ascending colon [22]. Thus, segmental con-
tractions in the colon act as a functional brake of the flow of intraluminal contents.
This gives the colonic mucosa time to fully absorb water and electrolytes still present
in the intraluminal contents.
Colonic motility is controlled by the inherent rhythmicity of the colonic smooth
muscle. Continuous cyclical depolarization of the smooth muscle membrane is
called slow-wave activity. Spike potentials are superimposed on the slow waves and
they initiate the contractile process. Spike potentials occur at one phase of the slow-
wave cycle. Thus, the frequency of the slow waves determines the contractile fre-
quency of the colonic smooth muscle. Any disease process which alters either the
slow-wave pattern or the spike response to physiologic stimuli will alter the pattern
of contraction and thus the flow of luminal contents.
CONSTIPATION IN PATIENTS WITH DIABETES MELLITUS
In patients with diabetes mellitus whose major complaint is constipation, the co-
lonic slow-wave pattern is similar to the one present in healthy controls [17]. In
healthy controls, slow waves predominantly occur at a frequency of 6 cycles/
minute. The slow wave frequency in patients with diabetes mellitus is also 6 cycles/
minute. Thus, if the colon responds to physiologic or pharmacologic stimuli, the
contractile pattern should be similar to that of healthy subjects.
When fasting, spike activity is minimal in both healthy subjects and patients with
diabetes mellitus. In healthy subjects, spike activity increases rapidly after eating a
meal. In healthy subjects, spike activity superimposed on slow waves increases dur-
ing the first ten minutes postprandially and remains elevated for thirty minutes after
eating. The pre-administration of an anticholinergic drug inhibits the postprandial
increase in spike activity. Either oral or intravenous administration of an an-
ticholinergic drug will inhibit colonic spike and contractile activity. Thus, the
postprandial gastrocolonic response appears to be mediated through the cholinergic
nervous system.
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In these patients the gastrocolonic response to eating is disturbed. After a
1,000-calorie meal, diabetic patients with constipation have no increase in colonic
spike activity. In those patients with normal bowel habit, the postprandial spike
response is similar to that of healthy controls. These data suggest that the
gastrocolonic response to a meal is abnormal in diabetic patients.
Previous studies in patients with diabetes mellitus have suggested that there are
motor disturbances throughout the gastrointestinal tract which are secondary to a
dysfunction of the autonomic nervous system. In the esophagus there is a dimin-
ished velocity of esophageal peristalsis in the presence of a normal contractile
response of the lower esophageal sphincter to edrophronium [4]. Histologic abnor-
malities of the parasympathetic nerve fibers and the myenteric ganglia in patients
with diabetes mellitus have been implicated as the cause of reduced gastric acid
secretion and delayed gastric emptying [23]. Small intestinal motility studies in
diabetic patients with diarrhea have shown a decreased response to intestinal disten-
tion but a normal response to the administration of catecholamines or cholinergic
drugs [7]. Sympathetic ganglia and the interneuronal pathways are degenerated in
diabetic patients [24]. These ganglia are important for the integration of impulses in
the various parts of the colon and may play an important role in the disordered con-
trol of gastrointestinal motility in patients with diabetes mellitus.
Dysfunction ofcolonic motility in diabetic patients may be primarily due to an ab-
normality in the autonomic neural control. The cholinergic nervous system appears
to be disturbed in diabetic patients whose major complaint is constipation, since the
gastrocolonic response is abnormal [17].
Previous studies have shown that the colonic smooth muscle is capable of being
stimulated in diabetic patients with constipation. Administration of a parasym-
pathomimetic drug, such as neostigmine or metoclopramide, can increase colonic
spike activity and colonic contractile activity [17]. Thus the smooth muscle appears
normally responsive in patients with diabetes mellitus despite the lack of a
gastrocolonic response.
The motor defect in patients with insulin-requiring diabetes mellitus and constipa-
tion may be at several levels. The defect in the neuroreceptors in the mucosa of the
upper gastrointestinal tract may cause abnormalities in the gastrocolonic response.
Blocking neuroreceptors with procaine has abolished the gastrocolonic motor
response [25]. Thus it is important to have intact mucosal receptors upon which the
dietary components can act. There also may be a defect in the long arc
gastrointestinal reflex. There are defects in the prevertebral and paravertebral sym-
pathetic ganglia important to the control of colonic function, as previously de-
scribed [7]. Furthermore, there are abnormalities in autonomic nerve conduction
which may be important in the control ofthe gastrocolonic response. Further studies
are needed to evaluate these hypotheses.
Attempts to correlate the degree of peripheral neuropathy with the severity of
motor abnormalities in various segments of the gastrointestinal tract have been
variable [4,5,17,19]. We found no correlation between peripheral nerve conduction
velocities and postprandial colonic myoelectric and motor activity in diabetic pa-
tients with varying degrees of constipation. Similarly, we found no correlation be-
tween gastric emptying of a liquid meal and colonic motility or between peripheral
nerve conduction velocity and gastric emptying [17]. This suggests that patchy in-
volvement of the autonomic nervous system occurs and may explain the variable
manifestations of diabetic enteropathy in an individual patient.
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DIARRHEA IN PATIENTS WITH DIABETES MELLITUS
Diarrhea is a much less common problem in patients with diabetes mellitus. In a
recent survey only 22 percent of diabetic outpatients complained of diarrhea (loose
stools or frequency). The episodes of diarrhea were mostly acute and intermittent
[3].
Certain chronic disorders which can cause increased stool volume (weight greater
than 200 g/day) are seen with increased frequency in diabetics. These conditions are
celiac sprue (gluten-sensitive enteropathy), pancreatic insufficiency, and bacterial
overgrowth of the small intestine [3]. These conditions, plus other causes of non-
diabetic diarrhea, must be excluded before a diagnosis of idiopathic diabetic diar-
rhea can be made.
The cause of idiopathic diabetic diarrhea is not known but multiple factors may
be responsible for the pathogenesis [3]. Colonic motility has not been measured in
diabetic patients with diarrhea, but colon dilation may occur in patients with noctur-
nal diarrhea associated with diabetes mellitus [11].
Fecal incontinence is often associated with chronic diarrhea in diabetic patients
[14] and is a common but often unmentioned episodic problem in diabetics without
diarrhea [3]. The cause of fecal incontinence appears to be related to weakened con-
tractions of the internal anal sphincter [14].
Disordered small intestinal motility may be the major cause of the diarrhea in
diabetic patients. Degeneration of the interneuronal pathways controlling small in-
testinal smooth muscle function may cause the decreased tone and increased
amplitude of phasic small intestinal contractions [7,26]. The myenteric plexus ap-
pears functional, since there was no hypersensitivity to methacholine.
The information currently available suggests that both diarrhea and constipation
in patients with diabetes mellitus are due to autonomic neural dysfunction. When
neural control ofthe colon is disrupted, constipation results. When neural control of
the small intestine is disrupted, diarrhea may be the result.
TREATMENT
Management of the symptoms relating to diabetic colonic dysfunction has not yet
been extensively evaluated. We have developed a regimen based on general measures
and the results of the limited pathophysiologic studies performed to date. Our ap-
proach is outlined in Table 2.
Constipation is the most common symptom of diabetic colonic dysfunction. A
simple increase in dietary fiber may reduce intestinal transit time. Some high-fiber
TABLE 2
Treatment of Colonic Dysfunction in Diabetes
Constipation Diarrhea
High-fiber diet Diphenoxylate with atropine
General Psyllium Loperamide
Lactulosea
Stool softeners, Enemas Biofeedback
(fecal incontinence)
SeBethanecol
Symptoms Pyridostigmine
Metoclopramide
aLarge doses may elevate the blood sugar.
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foods may lead to increased gas production. Therefore, the quantity of fiber in the
diet should be increased gradually to avoid excessive flatulence and bloating. There
is recent evidence that fiber improves glucose tolerance and reduces insulin re-
quirements. Thus patients should be cautioned that the need for insulin or oral
hypoglycemic agents may be decreased [27]. Supplement with a hydrophillic
mucilloid psylium preparation is a practical method of increasing stool bulk.
Lactulose has recently been proposed for use in chronic constipation. This non-
absorbing carbohydrate is degraded by the colonic bacteria to low molecular weight
fatty acids which act as osmotically active particles. The acid pH and increased
osmotic activity stimulate colonic propulsive activity. The commercial preparation
of lactulose syrup (Chronulac) contains small quantities of galactose, lactose, and
other sugars. Therefore, it should be used with caution in diabetics. We have found
small quantities (10 cc by mouth, twice a day) of lactulose useful in some patients
and have observed no appreciable effect on blood sugar.
Periodic usage ofstool softeners, mineral oil, or enemas may be needed to prevent
fecal impaction. Patients should be counseled against chronic laxative usage, par-
ticularly theanthraquinone group (senna, cascara, aloes) [28]. These substances may
produce progressive toxic damage to the intrinsic nerve plexuses of the colon, thus
aggravating an already existing autonomic neuropathy of the gastrointestinal tract.
A small group ofpatients with advanced diabetic enteropathy may develop severe
constipation or obstipation that is unresponsive to the above measures. These pa-
tients may benefit from a pharmacologic trial of drugs which stimulate the colonic
smooth muscle. Cholinergic agents such as bethanechol (cholinergic agonist) or
pyridostigmine (cholinesterase inhibitor) can be tried. Recently metoclopramide
(Reglan) has been approved for treatment of diabetic gastroparesis, and we have
observed an improvement in severe constipation during treatment of diabetic
gastropathy [17]. This clinical observation is consistent with the cholinergic-like
stimulatory effect of metoclopramide on colonic smooth muscle [17]. Meto-
clopramide also suppresses the chemoreceptor trigger zone ofthe vomiting pathway
and is, therefore, a powerful antimetic [29].
In some diabetic patients with colonic dysfunction, diarrhea, with or without in-
continence, may be the predominant manifestation. Several studies have
demonstrated the efficacy of both loperamide and diphenoxylate with atropine in
the treatment of chronic diarrhea [30]. Temporary or intermittent therapy using
these agents has been very helpful among our diabetic population.
Two recent studies evaluated biofeedback conditioning for fecal incontinence
related to various medical disorders [15,31]. A small number of diabetic patients
were among those studied. Patients were taught to develop reflex transient contrac-
tion of the external sphincter in response to rectal distention. Ability to sense rectal
distention was a major prerequisite for successful conditioning. Cerulli and
associates found a poor response in the one diabetic patient they evaluated [31].
Most of the patients in their poor-response group were felt to have lesions involving
the afferent nerve pathways with loss of sensation. Wald studied five insulin-
dependent diabetics with peripheral neuropathy and fecal incontinence [15]. Three
patients improved dramatically with biofeedback conditioning, suggesting that this
may be a valuable therapeutic modality in some diabetic patients with fecal incon-
tinence.
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